Teva’s Digihaler™ has been FDA approved for use with ProAir® (albuterol sulfate 117 mcg), AirDuo® (fluticasone propionate and salmeterol), and ArmonAir® (fluticasone propionate) inhalers. The Digihaler™ contains built-in sensors that records inhalation data with timestamps. The inhalation data includes parameters that are important for assessing inhaler technique including peak inspiratory flow rate and inhalation duration [27]. The device is connected via Bluetooth® technology to a companion App that provides information on inhaler use to the patient. While to date, the efficacy of Digihalers has not been evaluated; one pilot study has shown its ability to predict exacerbations [28]. Adults with exacerbation-prone asthma (n = 360) used the ProAir® Digihaler™ for 12 weeks. The Digihaler™ was able to predict asthma exacerbations (defined as need for oral corticosteroids) with an area under the receiver operating characteristic curve of 0.75. The most predictive factor was the average number of albuterol inhalations per day during a period of 5 days before an exacerbation. Further developments of the model in larger populations are needed to determine the efficacy of the Digihaler™ to predict exacerbations.